Quantia / Brain tumors and methylated C-MET

Nice presentation on Quantia. They presented a case of a "disruptive Doctor" who was reported by staff as being "late", "not responsive to call" and "being rude to staff". Pretty much led me to agree with them. But through due process, heard the Dr's response to these accusations, I was able to give him some slack and another chance. Often we rush to condemnation without knowledge of other people's values and perspective. The key to finding the truth is due diligence! The lack of institutional due diligence led to misconstruction and mistakes!
We also attended a talk on Brain tumor, one of the resistant cancers, about importance of finding methylated C-MET as it gives a positive prognosis, responsiveness to treatment, and high pseudo-progression rate on MRI. This all is relevant to our Targeting therapy. An interesting observation to make is that, in cancers that are resistant, the response rate is consistently hovering around 15-30%. This is seen with Avastin in Brain cancers and Ipilimumab in Melanoma. This is pointing to the fact that we still have not reached the main target to apoptosis, or that we need sequential additional hits, or have not closed a loophole! We need to go back to the drawing board!